Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
Journal: Oncogene
Published:
Abstract
Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.
Authors
Zhenyi An, Ozlem Aksoy, Tina Zheng, Qi-wen Fan, William Weiss
Relevant Conditions